Echinatin Ameliorates Insulin Resistance and Hepatic Lipid Accumulation in db/db Mice

Background: Type 2 diabetes mellitus (T2DM) is a multifactorial metabolic disorder characterized by hyperglycemia, insulin resistance, hepatic steatosis, chronic inflammation, and oxidative damage. Echinatin (ECH), a naturally occurring chalcone compound, has shown potential metabolic regulatory activities, but its effects and underlying mechanisms in T2DM remain unclear. This study aimed to investigate the effects of ECH and its underlying mechanisms in db/db mice. Methods: Male db/db mice were orally administered ECH at low and high doses for 8 weeks. Glucose metabolism was evaluated by fasting blood glucose measurement and oral glucose tolerance test (OGTT). Insulin sensitivity was assessed by serum insulin levels and hepatic AKT phosphorylation. Pancreatic β-cell integrity was examined by insulin immunohistochemistry. Hepatic glucose metabolism-related genes, including Pck1, G6pc, Gys1, Gys2, Gck, and Slc2a2, were analyzed by quantitative PCR. Serum and hepatic lipid profiles, hepatic steatosis, inflammatory cytokines, and oxidative stress markers were also evaluated. Results: ECH treatment significantly reduced fasting blood glucose levels and improved glucose tolerance, as indicated by ECH-preserved pancreatic β-cell integrity and increased serum insulin levels. Furthermore, ECH enhanced hepatic insulin signaling, as demonstrated by an increased p-AKT/AKT ratio. At the transcriptional level, high-dose ECH significantly suppressed the expression of gluconeogenic genes Pck1 and G6pc, while upregulating the glucose transporter gene Slc2a2 without significantly altering Gys1, Gys2, or Gck expression. In addition, ECH reduced serum and hepatic triglyceride and total cholesterol levels, alleviated hepatic lipid accumulation by H&E and Oil Red O staining, and decreased circulating inflammatory cytokines (TNF-α and IL-1β) and oxidative markers (4-HNE and 8-OHdG). Conclusions: ECH treatment was associated with improvements in multiple metabolic parameters in db/db mice, including glucose homeostasis, insulin sensitivity, hepatic steatosis, and systemic inflammation and oxidative stress. These observations may provide a basis for further studies on the effects of ECH on T2DM-related glucose and lipid metabolism.

Authors

Institutions

Publication Details

Journal
Biomedicines
Published
2026-09-17
DOI
https://doi.org/10.3390/biomedicines14092091
Primary Topic
Natural Antidiabetic Agents Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Echinatin Ameliorates Insulin Resistance and Hepatic Lipid Accumulation in db/db Mice

Lijie Jiang, Jingqing Hu, Hong Xu, Yuanjun Zhang
Biomedicines
Natural Antidiabetic Agents Studies
article

Echinatin Ameliorates Insulin Resistance and Hepatic Lipid Accumulation in db/db Mice

Lijie Jiang, Jingqing Hu, Hong Xu, Yuanjun Zhang
article en

Abstract

Background: Type 2 diabetes mellitus (T2DM) is a multifactorial metabolic disorder characterized by hyperglycemia, insulin resistance, hepatic steatosis, chronic inflammation, and oxidative damage. Echinatin (ECH), a naturally occurring chalcone compound, has shown potential metabolic regulatory activities, but its effects and underlying mechanisms in T2DM remain unclear. This study aimed to investigate the effects of ECH and its underlying mechanisms in db/db mice. Methods: Male db/db mice were orally administered ECH at low and high doses for 8 weeks. Glucose metabolism was evaluated by fasting blood glucose measurement and oral glucose tolerance test (OGTT). Insulin sensitivity was assessed by serum insulin levels and hepatic AKT phosphorylation. Pancreatic β-cell integrity was examined by insulin immunohistochemistry. Hepatic glucose metabolism-related genes, including Pck1, G6pc, Gys1, Gys2, Gck, and Slc2a2, were analyzed by quantitative PCR. Serum and hepatic lipid profiles, hepatic steatosis, inflammatory cytokines, and oxidative stress markers were also evaluated. Results: ECH treatment significantly reduced fasting blood glucose levels and improved glucose tolerance, as indicated by ECH-preserved pancreatic β-cell integrity and increased serum insulin levels. Furthermore, ECH enhanced hepatic insulin signaling, as demonstrated by an increased p-AKT/AKT ratio. At the transcriptional level, high-dose ECH significantly suppressed the expression of gluconeogenic genes Pck1 and G6pc, while upregulating the glucose transporter gene Slc2a2 without significantly altering Gys1, Gys2, or Gck expression. In addition, ECH reduced serum and hepatic triglyceride and total cholesterol levels, alleviated hepatic lipid accumulation by H&E and Oil Red O staining, and decreased circulating inflammatory cytokines (TNF-α and IL-1β) and oxidative markers (4-HNE and 8-OHdG). Conclusions: ECH treatment was associated with improvements in multiple metabolic parameters in db/db mice, including glucose homeostasis, insulin sensitivity, hepatic steatosis, and systemic inflammation and oxidative stress. These observations may provide a basis for further studies on the effects of ECH on T2DM-related glucose and lipid metabolism.

BiomedicinesVol. 14(9)
Tianjin University of Traditional Chinese Medicine (CN), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), China Academy of Chinese Medical Sciences (CN), Chengdu University of Traditional Chinese Medicine (CN)
Good health and well-being
Openalex Percentile: Top 10%
Natural Antidiabetic Agents Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.